Semaglutide reduces COVID-19 related deaths in patients with obesity and cardiovascular diseaseSemaglutide reduces COVID-19 related deaths in patients with obesity and cardiovascular disease
Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease (CVD) without diabetes, according to a new study published in JACC. The results will be published simultaneously with a presentation at the European Society of Cardiology (ESC) Conference 2024 in Read More
Study finds weight loss drug semaglutide reduced COVID-19 related deaths during the pandemicStudy finds weight loss drug semaglutide reduced COVID-19 related deaths during the pandemic
Patients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an international study led by researchers from Brigham and Women’s Hospital, a founding member of the Mass General Brigham health care system, finds. The randomized, controlled SELECT Trial, funded by Novo Nordisk, studied the effect Read More
Ozempic, Wegovy have health benefits beyond weight loss, studies findOzempic, Wegovy have health benefits beyond weight loss, studies find
New trials are showing how the blockbuster diabetes and weight-loss meds Ozempic and Wegovy can boost health in even more ways. New trials are showing how the blockbuster diabetes and weight-loss meds Ozempic and Wegovy can boost health in even more ways.
STAT+: Pharmalittle: We’re reading about Wegovy study results, an Alnylam heart drug, and moreSTAT+: Pharmalittle: We’re reading about Wegovy study results, an Alnylam heart drug, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, so far, is rather modest. We plan to promenade with the official mascots, spend time with our Pharmalot ancestor, and catch up on Read More
Wegovy Protects Against Deadly COVID CasesWegovy Protects Against Deadly COVID Cases
(MedPage Today) — LONDON — The clinical benefits of semaglutide (Wegovy) went beyond expectations in the SELECT trial, given the reductions in non-cardiovascular and infectious disease deaths observed. Among people with overweight or obesity… (MedPage Today) — LONDON — The clinical benefits of semaglutide (Wegovy) went beyond expectations in the SELECT trial, given the Read More
STAT+: Wegovy cut patients’ chances of dying from Covid-19, new analysis showsSTAT+: Wegovy cut patients’ chances of dying from Covid-19, new analysis shows
LONDON — Novo Nordisk made worldwide headlines last year when a study demonstrated that Wegovy, its powerful and exceedingly popular weight loss medicine, helped reduce the risk of cardiovascular emergencies like heart attacks. Researchers on Friday unveiled results demonstrating another benefit that the drug offered to patients in that study: Compared to placebo, it cut Read More
STAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failureSTAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure
Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to expand the label for the blockbuster treatment. Researchers combined data on nearly 4,000 patients across four trials who had heart failure with reduced Read More
Benefits of Neoadjuvant Immunotherapy in Breast Cancer Extend Beyond TNBCBenefits of Neoadjuvant Immunotherapy in Breast Cancer Extend Beyond TNBC
(MedPage Today) — Neoadjuvant, but not adjuvant, chemoimmunotherapy significantly improved key outcomes in certain patients with early breast cancer, according to a meta-analysis involving more than 5,000 patients.
Consistent with existing evidence…
Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategyJim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy
What’s behind the “great abandonment” in gene therapy R&D? How does a startup spend $213 million? And is Adam an optimist? We talk about all that and more on this week’s episode of “The Readout LOUD.” STAT biotech reporter Jonathan Wosen joins us to discuss gene therapy pioneer Jim Wilson’s exit from his decades-long tenure Read More
STAT+: Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and moreSTAT+: Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and more
Rise and shine, everyone, another busy day is on the way. We can tell because the official mascots are barking at an unusually high number of doggies walking alongside the Pharmalot campus this morning and the number of motor cars driving by. And we are trying to keep pace. To do so, yes, we are Read More